#China #Shanghai #AI Biotech #Ailux #Maria Belvisi

Maria Belvisi Takes Charge at Ailux

In a strategic move, Ailux, an innovative biotech company known for its AI-driven biologics discovery, has appointed Maria G. Belvisi, Ph.D., as its new Chief Scientific Officer (CSO) as of April 9, 2026. Dr. Belvisi joins Ailux from AstraZeneca, where she held the position of Senior Vice President in the Research & Development division, specifically focusing on Respiratory and Immunology. With over three decades of robust experience in both academic and industry settings, her addition is anticipated to significantly boost Ailux's efforts in drug development, aiming for first clinical entry by 2027.

A Dynamic Leader in Biopharma

Dr. Belvisi’s career is marked by her exceptional contributions to the field of drug research, most notably her role at AstraZeneca, where she led a team of around 500 scientists across multiple countries. Her leadership in fostering one of the most effective early respiratory development organizations has been acclaimed in the pharmaceutical industry. Notably, she has driven the promising antibody tozorakimab through various stages, achieving critical milestones in major clinical trials for Chronic Obstructive Pulmonary Disease (COPD).

In her capacity at AstraZeneca, Dr. Belvisi was responsible for the entire process from target identification to investment decisions for late-stage clinical research. Her success in bringing innovations from the lab to the clinic equips her with the critical skills necessary for Ailux as it seeks to navigate through complex drug development pathways.

Transforming Ailux's Vision

Ailux, founded within and entirely owned by XtalPi, is keen on integrating advanced AI technologies with biopharmaceutical research. The company aims to discover and engineer next-generation therapeutics that can address unmet medical needs across various diseases. Dr. Belvisi's appointment is viewed as a significant catalyst in steering the company's scientific strategy and developing new programs. She will oversee the establishment of a research site in the UK, which will complement the company's existing research capabilities in Shanghai.

CEO Alex Li expressed confidence in Dr. Belvisi’s ability to lead Ailux towards its ambitious goals. He articulated that her extensive experience in turning bold scientific theories into tangible medical solutions is exactly what Ailux needs at this juncture. This leadership change signals Ailux's commitment to building a robust pipeline of innovative drugs that leverage AI technologies.

A Bright Future for Patients

Expressing her enthusiasm about joining Ailux, Dr. Belvisi stated that the company exemplifies a unique integration of AI and biology, setting it apart from traditional drug discovery practices. She believes that this revolutionary approach provides a conducive environment for developing first-in-class and best-in-class therapies.

In addition to her pivotal role at Ailux, Dr. Belvisi maintains her professorship at the National Heart and Lung Institute of Imperial College London, where her influence extends to mentoring the next generation of scientists. Her scholarly contributions, with over 250 published papers, underline her dedication to advancing medical science.

Ailux’s commitment to innovation and its proactive strategies under Dr. Belvisi's leadership hold promise for a future where transformative therapies could become accessible to patients worldwide, significantly enhancing their quality of life.

Ailux is set to revolutionize the biotech landscape, driven by the integration of AI into its core operations, and backed by an experienced leader ready to tackle the challenges ahead. Ailux stands at the precipice of potential breakthroughs in drug development, thanks to the foresight and expertise brought by Dr. Belvisi.

As the biotech industry progresses, the role of leaders like Dr. Belvisi cannot be understated. Her journey at Ailux will certainly be one to watch, as the intersection of AI and biology continues to inspire groundbreaking medical advancements.